A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

Thanks to research advances, two new effective prevention methods are now available. The first is nirsevimab, which is approved and recommended for infants 0–8 months old and select older ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory ...

They also may have implications for when the RSV monoclonal antibody, Nirsevimab, should be administered to newborns. Similar research should be conducted for other vaccines administered during ...

Seasonal maternal RSV vaccination may be cost-effective, particularly for those with higher risks. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab ...

Jessica and Ellie Parker both took part in the Harmonie trial Nirsevimab, developed by AstraZeneca and Sanofi, was licensed for use in the UK last year. The Joint Committee on Vaccination and ...